The paper analyzes pre-beta burst dynamics in Parkinson's disease to separate genuine neural beta-burst activity from recording artifacts.

Improving discrimination of true beta-burst signals could refine electrophysiological biomarkers and DBS tuning with translational relevance, but absence of an abstract and limited mechanistic or therapeutic content reduce its direct value for drug discovery.